Freenome, a high-profile startup that aims to develop a blood test to detect colon cancer, has quietly replaced its co-founder and chief executive, Gabriel Otte.
The company’s chief business officer, Mike Nolan, a long-time veteran of the genomics and diagnostic industries, is Freenome’s new CEO. He was identified as such in a Freenome press release on Friday about new data on its experimental test; he is also listed as CEO on Freenome’s website and on his own LinkedIn profile.
However, Freenome made no public announcement of the change. A company spokesman, reached by STAT, confirmed that Nolan, who previously worked at Foundation Medicine and Thermo Fisher, had replaced Otte as CEO.